文献速递湿疹皮炎与荨麻疹

PEDISTAD 注册研究:肤色对中重度特应性皮炎患儿系统治疗转归的影响(4年结果)

Real-world systemic treatment outcomes for moderate-to-severe atopic dermatitis in children by skin color: 4-year results from the observational, international, real-world PEDISTAD registry.
PubMed 文献 · J Am Acad Dermatol · 2026-09-21

PEDISTAD 是一项观察性、国际、真实世界研究,纳入 314 例白人儿童和 186 例非白人儿童(<12 岁),比较中重度特应性皮炎(AD)对系统治疗的反应。结果显示,无论肤色/种族,接受度普利尤单抗治疗的患者在临床医生报告和患者报告的转归方面均优于甲氨蝶呤和环孢素。

要点

  • 度普利尤单抗在非白人和白人儿童中均显著改善 EASI 和瘙痒评分。
  • 环孢素在本研究中减少瘙痒的效果最差。
  • 度普利尤单抗的生活质量改善优于甲氨蝶呤或环孢素,两组相似。

核心结论

  • 无论肤色/种族,接受度普利尤单抗治疗的患者在临床医生报告和患者报告的转归方面均优于接受甲氨蝶呤和环孢素的患者。

研究设计与样本

  • PEDISTAD 是一项观察性、国际、真实世界研究。
  • 分析纳入 314 例白人儿童和 186 例非白人儿童(<12 岁),非白人包括黑人/非裔美国人、亚洲人、美洲印第安人或阿拉斯加原住民以及多种族。

主要发现

  • 非白人儿童中,度普利尤单抗、甲氨蝶呤和环孢素分别使 EASI 改善 13.6、8.2 和 9.2 分;白人儿童分别改善 14.2、10.1 和 4.5 分。
  • 度普利尤单抗在两个亚组中均显著改善瘙痒评分。
  • 环孢素在本研究中减少瘙痒的效果最差。
  • 度普利尤单抗的生活质量指标改善优于甲氨蝶呤或环孢素,两组相似。
  • 暴露调整不良事件率在白人儿童中最高:度普利尤单抗、甲氨蝶呤和环孢素分别为 33.33、33.24 和 58.33 事件/100 人年,非白人儿童分别为 28.28、20.86 和 28.72 事件/100 人年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) can have different genetic, immunopathogenic, and clinical features depending on the ethnicity of the affected individual. OBJECTIVE: To investigate if White and non-White children with moderate-to-severe AD respond differently to systemic treatment. METHODS: PEDISTAD is an observational, international, real-world study. Patients were analyzed in 2 subgroups: non-White and White. Non-White included Black/African American, Asian, American Indian or Alaskan-Native and Multiracial. RESULTS: 314 White, and 186 non-White children <12 years were included. Eczema-area-and-severity-index improved significantly for all: 13.6, 8.2, and 9.2 point-improvement with dupilumab, methotrexate and cyclosporine, respectively (non-White); and 14.2, 10.1, and 4.5 point-improvement (White). Itch scores improved significantly with dupilumab for both subgroups. Cyclosporine was the least effective at reducing itch in this study. Quality-of-life metrics were observed to improve similarly in both groups with dupilumab, to a greater extent than with methotrexate or cyclosporine. The exposure-adjusted adverse event rate was highest in White children: 33.33, 33.24, and 58.33 events/per 100 person years for dupilumab, methotrexate and cyclosporine respectively, versus 28.28, 20.86, and 28.72 events/100 person years in the non-White children. CONCLUSION: In this study, patients that received dupilumab had a greater observed improvement in clinician- and patient-reported outcomes compared with patients receiving methotrexate and cyclosporine irrespective of skin color/race.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Paller AS, Eichenfield LF, Wine Lee L, et al. Real-world systemic treatment outcomes for moderate-to-severe atopic dermatitis in children by skin color: 4-year results from the observational, international, real-world PEDISTAD registry. J Am Acad Dermatol. 2026. PMID: 42767466. doi:10.1016/j.jaad.2026.09.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。